Categories: News

Moderna to Provide Business and Pipeline Updates at the 2022 J.P. Morgan Healthcare Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CAMBRIDGE, MA / ACCESSWIRE / January 3, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at the virtual 40th annual J.P. Morgan Healthcare Conference on Monday, January 10th at 8:15 a.m. ET.

A live webcast of the presentation will be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

Moderna Contact

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View source version on accesswire.com:
https://www.accesswire.com/680608/Moderna-to-Provide-Business-and-Pipeline-Updates-at-the-2022-JP-Morgan-Healthcare-Conference

Staff

Recent Posts

NUTEX HEALTH ANNOUNCES INTERNET AVAILABILITY OF PROXY MATERIALS FOR ITS 2025 ANNUAL MEETING

HOUSTON, June 2, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:…

4 hours ago

Sony, SCREEN, and VitroVo to Start Trial Offer of MEA System Capable of Simultaneous Measuring and Recording Data from Approximately 237,000 Electrodes

Contributing to high-definition visualization of cellular activity and supporting research into neuronal and cardiac diseases…

4 hours ago

PAIG AI Rebrands as Trust3 AI to Lead the Way in Trusted AI Adoption

SAN FRANCISCO, June 2, 2025 /PRNewswire/ -- PAIG AI, a leading provider of AI governance…

4 hours ago

Delivra Health Brands, and Its Dream Water(R) Brand, Partners with QVC to Bring Dream Water to Online Shoppers Across the US

Vancouver, British Columbia--(Newsfile Corp. - June 2, 2025) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB:…

11 hours ago

Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering

Philadelphia, Pennsylvania--(Newsfile Corp. - June 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company")…

14 hours ago

Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation

ARLINGTON, Va.--(BUSINESS WIRE)--The National Evaluation System for health Technology (NEST), an initiative of the Medical…

16 hours ago